Cat. #162058
Anti-deltaNp63 [deltaNp63-1.1]
Cat. #: 162058
Sub-type: Primary antibody
Target: tumour protein p63 lacking the transactivation domain (TA)
Class: Monoclonal
Reactivity: Human ; mouse ; rat
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Moravian Biotechnology
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-deltaNp63 [deltaNp63-1.1]
- Clone: deltaNp63-1.1
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 72 kDa
- Reactivity: Human ; mouse ; rat
- Host: Mouse
- Description: Antibody created to detect the deltaN isoform of p63 (deltaNp63) with tumour suppressor role and differentiate from the TA (TAp63) isoforms of the same protein. Binding specificity: within MLYLENNAQTQFSE. No cross-reaction with p53 or p73 isoforms. Specificity verified by CRISPR-knockout and shRNA knockdown.
- Immunogen: peptide MLYLENNAQTQFSE of tumour protein p63 (deltaN isoform) coupled to keyhole limpet hemocyanin
- Isotype: IgG1 kappa
- Production details: B cell donor: Splenocytes from mouse immunised with peptide MLYLENNAQTQFSE, Fusion partner: SP2
Target Details
- Target: tumour protein p63 lacking the transactivation domain (TA)
- Molecular weight: 72 kDa
- Target background: p63 is a transcription factor of the p53 gene family, encoded by the TP63 gene located at chromosome 3q28. p63 exists as N-terminal isoforms that either contain (TAp63) or lack (deltaNp63) the p53-like transactivation domain at the N-terminus. C-terminal isoforms are produced by alternative splicing of 3' exons. TAp63 is involved in germ cell maintenance and myocyte differentiation, and is expressed in some lymphocytes and lymphomas/leukemias.
- Epitope sequence: MLYLENNAQTQFSE sequence of tumour protein p63 (deltaN isoform)
Handling
- Format: Liquid
References
- Orzol et al. 2016. Tumour Biol. Aug:37(8):10133-40. PMID: 26825981
- Galoczova et al. 2021. Virchows Arch. Apr:478(4):627-636. PMID: 33037932
- Pokorna et al. 2022. Front Oncol. Jul 14:12:924354. PMID: 35912168
